Alpha Biopharma
Alpha Biopharma is a China-based clinical-stage biopharmaceutical company developing Zorifertinib, a first-in-class EGFR TKI with 100% blood-brain barrier penetration for EGFR-mutant NSCLC with CNS metastases, plus a cell therapy pipeline via its Wugen Inc. partnership.
- Company typePrivate
- Founded2017
- HeadquartersHuangpu, China
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What Alpha Biopharma does
Alpha Biopharma (晨泰医药 / Jiangsu Chentai Pharmaceutical Technology Co., Ltd.) is a China-based, privately held clinical-stage biopharmaceutical company founded in 2017. It specializes in innovative oncology drugs from clinical development through commercialization, with operations concentrated in mainland China (offices in Shanghai and Beijing; ICP-registered in Jiangsu) and a headcount of 51–100. The company is backed by domestic and foreign venture funds including Qiming Venture Partners, LYZZ Capital, and TF Capital, and has been recognized repeatedly on Great Wall Consultants' "Potential Unicorn" lists and as a Jiangsu Province technology-based enterprise.
The company's commercial and clinical centerpiece is Zorifertinib (泽瑞尼® / 盐酸佐利替尼片, originally AZD3759), a next-generation EGFR tyrosine kinase inhibitor approved and listed in China's national medical insurance (医保) as of July 2025. It is a Category 1 new drug (1类新药) supported by the National Major Project for New Drug Innovation, indicated for first-line treatment of EGFR-mutated (exon 19 deletion or L858R) locally advanced or metastatic non-small cell lung cancer (NSCLC) with central nervous system (CNS) metastases. Its differentiating technical claim is 100% blood-brain barrier penetration enabled by a non-efflux-protein-substrate molecular design, validated in the Phase 3 EVEREST / CTONG1702-Arm 8 trial (published in The Lancet EClinicalMedicine, September 2023). The company also maintains an early-stage cell therapy pipeline — universal off-the-shelf Memory NK cells and fratricide-resistant CAR-T cells targeting solid tumors, T-cell malignancies, AML, and multiple myeloma — developed through an exclusive collaboration with Wugen Inc. announced in 2021.
Alpha Biopharma generates revenue through pharmaceutical product sales of Zorifertinib via direct distribution to hospital pharmacies and oncology centers across China, prescribed by oncologists. Pricing is not publicly disclosed and follows a prescription-based channel model; revenue mechanics are anchored to a single approved product serving one narrow indication (EGFR-mutant NSCLC with CNS metastases). The company has raised approximately $93.9 million in cumulative disclosed funding across four rounds from 2018 through 2024, and is led by founder Liu Zhonghai with James Liu (COO) and Joan Cai (CMO).
Alpha Biopharma firmographics
Firmographics- Name
- Alpha Biopharma
- Legal name
- 江苏晨泰医药科技有限公司
- Website
- https://alphabiopharma.com
- Company type
- Private
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Alpha Biopharma is a China-based clinical-stage biopharmaceutical company developing Zorifertinib, a first-in-class EGFR TKI with 100% blood-brain barrier penetration for EGFR-mutant NSCLC with CNS metastases, plus a cell therapy pipeline via its Wugen Inc. partnership.
- Ownership category
- akta.pro rank
Alpha Biopharma industry classification
Industry- Product category
- Oncology Pharmaceuticals
- NAICS
- Pharmaceutical and Medicine Manufacturing (3254), Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Oncology & Hematology Pharmaceuticals (HLAIAAAC)
- akta.pro secondary industries
- NK Cell Therapies (HLAAABAD), CAR-T & TCR-T Therapies (HLAAABAC)
Keywords
Where Alpha Biopharma is headquartered
LocationHeadquarters
- HQ city
- Huangpu
- HQ country
- China
- HQ region
- Asia
Offices2 records
Markets served
Alpha Biopharma business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
Revenue model
- Pharmaceutical Product Sales: Revenue generated from commercialized drug products, specifically Zorifertinib (泽瑞尼, generic name:盐酸佐利替尼片) which has been approved and included in medical insurance for treatment of EGFR-mutant NSCLC with CNS metastases.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
Alpha Biopharma product offering
Product offeringCore offering
Alpha Biopharma is a clinical-stage biopharmaceutical company that develops and commercializes innovative oncology drugs, led by Zorifertinib (泽瑞尼®/AZD3759), a next-generation EGFR TKI for first-line treatment of EGFR-mutant NSCLC with CNS metastases. The company also develops universal off-the-shelf Memory NK cell and CAR-T cell therapies in partnership with Wugen Inc. for solid tumors, T-cell malignancies, AML, and Multiple Myeloma.
Product overview
Alpha Biopharma (晨泰医药) operates two main product lines: (1) Marketed drug: Zorifertinib (泽瑞尼®/AZD3759), a next-generation EGFR TKI for EGFR mutation-positive NSCLC with CNS metastases, featuring 100% blood-brain barrier penetration; (2) Cell therapy pipeline: Universal 'off-the-shelf' Memory NK cells and CAR-T cells developed in partnership with Wugen Inc., targeting solid tumors, T-cell malignancies, AML, and Multiple Myeloma.
Differentiator
Problem solved
Functional benefit
Products and services
- Zorifertinib (泽瑞尼®) Next-generation EGFR TKI drug (generic name: 盐酸佐利替尼片) for first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR 19 exon deletion or 21 (L858R) substitution mutations and accompanied by CNS metastases. Features 100% blood-brain barrier penetration via a non-efflux protein substrate design. Available in 50mg and 100mg dosages; supported by China's National Major Project for New Drug Innovation as a Category 1 new drug.
- Universal Memory NK Cell Therapy
Quantifiable outcome
- 100% blood-brain barrier penetration rate
- +2 more outcomes
Companies that use Alpha Biopharma
Customer profileSegments1 record
Ideal customer profiles1 record
Alpha Biopharma technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Alpha Biopharma partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Wugen Inc.coreExclusive license and collaboration agreement with Wugen Inc., a clinical-stage biotechnology company developing novel universal natural killer (NK) and T-cell therapies for cancer treatment. Alpha Biopharma expanded its pipeline to manufacture universal 'off-the-shelf' Memory NK and CAR-T cells for treatment of solid tumors, T-cell malignancies, Acute Myeloid Leukemia, and Multiple Myeloma. This partnership gives Alpha Biopharma access to Wugen's innovative cell therapy platform technology.
Scale indicators3 records
Recent moves6 records
Expansion highlights5 records
Alpha Biopharma competitors and assessment
Company assessmentEmerging players
- ArriVent Biopharma: Emerging oncology-focused biopharma developing next-generation targeted therapies including EGFR-TKIs (firmonertinib). Comparable as a focused EGFR-TKI developer competing in adjacent segments of the NSCLC treatment landscape.
Direct peers
- Cstone Pharmaceuticals: China-based oncology-focused biotech with both small-molecule and biologics pipeline including lung cancer assets. Comparable in targeting NSCLC indications and pursuing NRDL access for innovative oncology therapies.
- Innovent Biologics: China-based biopharma commercializing innovative oncology biologics and small molecules (e.g., PD-1, biosimilars). Comparable in oncology focus, NRDL-driven commercialization model, and integrated clinical-to-commercial pipeline strategy.
- Genor Biopharma: China-focused oncology and immunology biopharma with a pipeline spanning innovative and biosimilar candidates. Comparable in Chinese hospital-channel commercialization and oncology pipeline strategy.
- Hansoh Pharmaceutical: Leading Chinese oncology biopharma developing EGFR-TKIs (e.g., furmonertinib) and other targeted therapies. Comparable as a China-domiciled, hospital-channel-driven oncology innovator with both marketed products and pipeline assets.
- Akeso (AkesoBiopharma): China-based biotech developing novel antibodies and bispecifics for oncology, including lung cancer candidates. Comparable in Chinese oncology innovation focus, NRDL strategy, and bispecific/antibody pipeline depth.
- Junshi Biosciences: Chinese biopharma with strong oncology pipeline including PD-1 and targeted therapies. Comparable as a Chinese innovation-focused oncology company with NRDL participation and integrated clinical development.
Broad incumbents
- AstraZeneca: Originated AZD3759 (Zorifertinib) and markets Tagrisso (osimertinib), the dominant EGFR-TKI globally and in China. Directly competes with Alpha Biopharma in EGFR-mutant NSCLC and shapes the standard of care Zorifertinib must outperform.
- BeiGene: Large Chinese oncology biotech with multiple approved targeted therapies (e.g., Brukinsa, Tevimbra) and a global commercial footprint. Comparable as a Chinese innovator that has scaled oncology drugs from clinical development to commercialization.
Others
- Wugen Inc. US-based clinical-stage biotech and Alpha Biopharma's exclusive partner for Universal Memory NK and CAR-T cell therapy platforms. Highly relevant not as a competitor but as the technology partner whose platforms underpin Alpha Biopharma's cell therapy pipeline.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks5 records
Key highlights7 records
Customer concentration
Alpha Biopharma social profiles
Digital presenceAlpha Biopharma financial estimates
Financial estimateRevenue estimate
Valuation estimate
Alpha Biopharma leadership team
Management profileNumber of profiles
Profiles3 records
Alpha Biopharma funding detail
Funding detailFunding overview
Funding rounds4 records
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Alpha Biopharma M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Alpha Biopharma
What does Alpha Biopharma do?
Alpha Biopharma is a clinical-stage biopharmaceutical company that develops and commercializes innovative oncology drugs, led by Zorifertinib (泽瑞尼®/AZD3759), a next-generation EGFR TKI for first-line treatment of EGFR-mutant NSCLC with CNS metastases. The company also develops universal off-the-shelf Memory NK cell and CAR-T cell therapies in partnership with Wugen Inc. for solid tumors, T-cell malignancies, AML, and Multiple Myeloma.
Is Alpha Biopharma a public or private company?
Alpha Biopharma is a private company. It is classified as venture growth investor backed and is currently operating.
When was Alpha Biopharma founded?
Alpha Biopharma was founded in 2017. It employs 51 to 100 people.
Where is Alpha Biopharma based?
Alpha Biopharma is headquartered in Huangpu, China, in the Asia region.
How does Alpha Biopharma make money?
One revenue line is on record: pharmaceutical Product Sales.
Who are Alpha Biopharma's main competitors?
ArriVent Biopharma is listed as an emerging player. Direct peers are Cstone Pharmaceuticals, Innovent Biologics, Genor Biopharma, Hansoh Pharmaceutical, Akeso (AkesoBiopharma) and Junshi Biosciences. Broad incumbents are AstraZeneca and BeiGene. Wugen Inc. is listed as an others.
Does Alpha Biopharma have an API?
No public API is recorded for Alpha Biopharma.
What industry is Alpha Biopharma in?
Alpha Biopharma's product category is Oncology Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAC, Oncology & Hematology Pharmaceuticals, with a secondary code of HLAAABAD, NK Cell Therapies. Its NAICS code is 3254 and its SIC code is 2834.